Harbaugh R E
Section of Neurosurgery, Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire.
J Neural Transm Suppl. 1987;24:271-7.
In June 1983, we began evaluating intracerebroventricular (ICV) cholinergic drug infusion in patients with biopsy-documented Alzheimer's disease (AD). An initial trial in four patients showed this treatment approach to be feasible, but objective improvement in cognitive or social function was not documented (Harbaugh et al., 1984; Harbaugh, 1986). A double-blind, placebo-controlled crossover study involving a larger number of patients has since been done. The results of this study, presented here, document a statistically significant improvement in some cognitive test results during periods of drug infusion. However, the clinical applicability of this treatment approach is still questionable. A collaborative, double-blind study evaluating activities of daily living and cognitive test results during drug and placebo infusion is presently underway and should better define the safety and efficacy of this treatment approach for patients with AD.
1983年6月,我们开始评估经活检证实患有阿尔茨海默病(AD)的患者脑室内(ICV)注射胆碱能药物的效果。最初对4名患者进行的试验表明这种治疗方法是可行的,但未记录到认知或社交功能的客观改善(哈博等人,1984年;哈博,1986年)。此后进行了一项涉及更多患者的双盲、安慰剂对照交叉研究。本文展示的这项研究结果表明,在药物注射期间,一些认知测试结果有统计学上的显著改善。然而,这种治疗方法的临床适用性仍值得怀疑。目前正在进行一项合作双盲研究,评估药物和安慰剂注射期间的日常生活活动和认知测试结果,这将更好地确定这种治疗方法对AD患者的安全性和有效性。